Abstract 2084P
Background
CV mortality is the leading preventable cause of death in cancer patients. Understanding the timing and quantifying the magnitude of CV mortality can facilitate strategies to reduce mortality.
Methods
Surveillance, Epidemiology, and End Results (SEER) database (2004-2018) were queried to obtain CV mortality (defined as deaths due to heart diseases, hypertension, cerebrovascular diseases, atherosclerosis, aortic aneurysm, and dissection) in metastatic cancer patients. Standardized mortality ratios (SMRs) were calculated (observed deaths from each category divided by the expected number of deaths in the age-matched US population for the same period). SMR was presented by latency periods of <2, 2-5, and >5 years after the initial diagnosis of metastatic cancer and stratified by age (<50 years, 50-70 years, >70 years), race (White, Black, Asian/Pacific Islander, Native American), and ethnicity (Hispanic, Non-Hispanic).
Results
This analysis included 914,804 metastatic cancer patients. Overall, the risk of CV death was highest <2 years of initial diagnosis (SMR: 2.47, 95% CI: 2.35-2.58) compared to population who died 2-5 years (1.22, 1.17-1.27) and 5>years (1.11, 1.03-1.17) after the initial diagnosis. In terms of different subgroups, younger population (age <50 years) observed the highest risk of CV mortality within < 2 years (8.84, 7.5-10.4) except for prostate cancer, where the risk of cardiovascular death becomes highest at >5 years after diagnosis. Similarly, regarding race, Native Americans had the highest risk of CV mortality (6.44, 4.86-8.54), which remained consistent across different cancers. There was significant increase in observed mortality in Hispanic (2.93, 2.62-3.28) and Non-Hispanic (2.43, 2.31-2.55) population. The mortality risk by ethnicity remained consistent with latency periods of <2, 2-5, and > 5years after the initial diagnosis of metastatic cancer.
Conclusions
Metastatic cancer patients who are younger or those who are Native Americans have the highest CV mortality, especially <2 years of initial diagnosis of metastatic disease. Targeted cardio-oncological strategies should be aimed at improving CV mortality in patients who are at highest risk of deaths.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
I.B. Riaz.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2045P - Patient Reported Outcome Measures (PROMs) capturing therapy adherence of cancer patients: A systematic literature review
Presenter: Luise Richter
Session: Poster session 06
2046P - The importance of communicating bad news in medical education
Presenter: Georgios Goumas
Session: Poster session 06
2047P - Neutrop: A descriptive, observational study for G-CSF prescription in daily practice
Presenter: Florian Scotté
Session: Poster session 06
2048P - Frequency and clinical relevance of drug-drug interactions with oxycodone among patients with cancer
Presenter: Lotte Hulskotte
Session: Poster session 06
2049P - Osimertinib-related muscle cramps as a common adverse event: A real-world data analysis in the post-approval setting
Presenter: Gisele Moreira
Session: Poster session 06
2050P - Integrating ayurveda herbs with standard of care for management of cancer or cancer treatment related anorexia
Presenter: Yogesh Bendale
Session: Poster session 06
2051P - E-PRO within comprehensive companion program for patients undergoing systemic cancer treatment to reduce emergency visits and inpatient admission in a Peruvian institution
Presenter: Patricia Rioja Viera
Session: Poster session 06
2052P - Adverse events in FLOT chemotherapy for locally advanced gastric cancer: An observational study of pre- and post-operative toxicity profiles
Presenter: Camila Oliveira
Session: Poster session 06
2053P - Dehospitalization through outpatient drug release in clinical pharmacy as a strategic cost-minimization action in a public oncology hospital in the Eastern Amazon: A quantitative analysis
Presenter: Kalysta Borges
Session: Poster session 06
2054P - Metastatic cancer patients hospitalized at initial diagnosis: When does rescue systemic therapy make sense? ONIRIS - A national, prospective study
Presenter: Colin Vercueil
Session: Poster session 06